Osteoporosis

01Pathophysiology

Bone is a dynamic tissue that undergoes continuous remodeling throughout life. This remodeling cycle depends on the coordinated activity of two cell types: osteoclasts, which resorb old or damaged bone, and osteoblasts, which lay down new bone matrix. In a healthy adult, these two processes are coupled so that the amount of bone removed roughly equals the amount of bone formed. Osteoporosis develops when this balance tips toward net bone resorption, resulting in decreased bone mineral density (BMD) and deterioration of the bone microarchitecture.

The most common and most tested mechanism is estrogen deficiency. Estrogen normally suppresses osteoclast activity by promoting osteoclast apoptosis and by inhibiting the production of pro-resorptive cytokines such as RANKL (receptor activator of nuclear factor kappa-B ligand), interleukin-1 (IL-1), interleukin-6 (IL-6), and tumor necrosis factor alpha (TNF-alpha). When estrogen levels drop after menopause, RANKL expression increases, osteoclast survival is prolonged, and bone resorption accelerates far beyond what osteoblasts can compensate for. This explains why the most rapid phase of bone loss occurs in the first 5 to 10 years after menopause and why the classic exam patient is a thin, postmenopausal woman presenting with a fragility fracture.

Glucocorticoid-induced osteoporosis follows a different but equally testable pathway. Chronic glucocorticoid exposure directly inhibits osteoblast differentiation and function while simultaneously promoting osteoblast and osteocyte apoptosis. In addition, glucocorticoids enhance RANKL expression and reduce the production of osteoprotegerin (OPG), the decoy receptor that normally neutralizes RANKL. The net effect is both increased resorption and decreased formation. Glucocorticoids also impair intestinal calcium absorption and increase renal calcium excretion, leading to secondary hyperparathyroidism that further accelerates bone loss. This is why patients on long-term prednisone (typically at doses of 5 mg/day or more for three months or longer) require prophylactic bone protection.

The clinical consequences follow directly from the structural changes. Trabecular bone, which has a higher surface area and faster turnover rate, is affected earlier and more severely than cortical bone. The vertebral bodies and distal radius are rich in trabecular bone, which is why compression fractures of the thoracolumbar spine and distal radius (Colles) fractures are early manifestations. The femoral neck contains both cortical and trabecular bone and tends to fracture later in the disease course but carries the highest morbidity and mortality, particularly in elderly patients.

The loss of vertebral body height from compression fractures produces the characteristic thoracic kyphosis and progressive height loss seen on examination. Because osteoporosis itself causes no pain until a fracture occurs, the disease is often called a "silent disease," and exam vignettes may present a patient whose first symptom is an acute fracture after minimal or no identifiable trauma.

02Classification and Clinical Manifestation

03Diagnostic Workup

DXA is both the best initial test and the most accurate test for osteoporosis. This is an important point for exam purposes because in most diseases, the screening test and the confirmatory test are different. In osteoporosis, DXA serves both roles. The measurement is reported as a T-score, which compares the patient's BMD to the mean BMD of a healthy 30-year-old reference population of the same sex. A T-score of $\le -2.5\backslash leq\; -2.5$ at the lumbar spine, femoral neck, or total hip confirms the diagnosis. A Z-score (which compares to age-matched peers) is used instead for premenopausal women, men under 50, and children; a Z-score of $\le -2.0\backslash leq\; -2.0$ is considered "below expected range for age" and should trigger evaluation for secondary causes.

Screening recommendations are frequently tested. DXA screening is indicated for: all women aged 65 and older, all men aged 70 and older, postmenopausal women under 65 with risk factors (low body weight, prior fracture, high-risk medication use, family history), and any adult with a fragility fracture regardless of age.

When DXA reveals osteopenia (T-score between $-1.0-1.0$ and $-2.5-2.5$), the FRAX tool helps determine whether pharmacologic treatment is warranted. Treatment is recommended if the FRAX-calculated 10-year probability of a major osteoporotic fracture is $\ge 20\backslash geq\; 20\%$ or the 10-year probability of a hip fracture is $\ge 3\backslash geq\; 3\%$.

Plain radiographs are not sensitive for early osteoporosis because bone density must decline by roughly 30% to 50% before radiographic changes become apparent. However, spine X-rays are valuable for detecting vertebral compression fractures that may be clinically silent. If a patient has documented height loss of more than 4 cm, a lateral spine radiograph or vertebral fracture assessment on DXA should be obtained.

Baseline laboratory workup is essential in every newly diagnosed patient to rule out secondary causes. A normal serum calcium, phosphorus, and alkaline phosphatase pattern helps distinguish primary osteoporosis from osteomalacia (where calcium and phosphorus are low and alkaline phosphatase is elevated) and from Paget disease (where alkaline phosphatase is elevated in isolation). Every patient should have a 25-hydroxyvitamin D level checked, as vitamin D deficiency is both a reversible contributor and a condition that must be corrected before starting bisphosphonate therapy.

04Management and Treatment

Acute Management of Osteoporotic Fractures:
A patient presenting with an acute vertebral compression fracture requires pain control as the immediate priority. Analgesics (acetaminophen, NSAIDs, or short-course opioids if needed) and early mobilization are the initial steps. Prolonged bed rest worsens bone loss and should be avoided. For patients with severe, refractory pain from vertebral compression fractures that do not respond to conservative measures after several weeks, vertebroplasty or kyphoplasty may be considered, though their long-term benefit over conservative management remains debated.

Hip fractures require urgent surgical fixation (within 24 to 48 hours when medically stable) followed by initiation of osteoporosis pharmacotherapy, typically with IV zoledronic acid given 2 weeks after surgical repair.

Long-term Pharmacologic Management:
The first-line treatment for most patients is an oral bisphosphonate (alendronate or risedronate). Bisphosphonates work by binding to hydroxyapatite in bone and being ingested by osteoclasts during resorption, where they inhibit the mevalonate pathway enzyme farnesyl pyrophosphate synthase, leading to osteoclast apoptosis. Patients must be counseled on proper administration: take the medication first thing in the morning on an empty stomach with a full glass (240 mL) of plain water, do not eat or drink anything else for at least 30 minutes, and remain upright (sitting or standing) to prevent esophageal irritation and ulceration.

Bisphosphonate therapy is typically continued for 5 years (oral) or 3 years (IV zoledronic acid), after which a "drug holiday" is considered for patients at moderate risk. Patients at high fracture risk may continue beyond these durations. Long-term bisphosphonate use (beyond 5 to 10 years) is associated with two rare but high-yield complications: osteonecrosis of the jaw (ONJ) and atypical subtrochanteric femur fractures. ONJ is particularly tested in the context of patients undergoing dental procedures while on bisphosphonates.

Denosumab is a human monoclonal antibody that binds RANKL, preventing its interaction with RANK on osteoclast precursors. It is given as a subcutaneous injection every 6 months and is a preferred option in patients with renal insufficiency (since it does not require renal clearance, unlike bisphosphonates). A critical exam pearl is that denosumab must never be abruptly discontinued because cessation causes a rapid rebound increase in bone resorption, leading to accelerated bone loss and a surge in vertebral fracture risk. Patients stopping denosumab should be transitioned to a bisphosphonate.

Teriparatide and abaloparatide are anabolic agents reserved for patients with severe osteoporosis (T-score below $-3.5-3.5$, multiple vertebral fractures, or fractures occurring despite antiresorptive therapy). Their use is limited to 2 years due to a theoretical risk of osteosarcoma observed in rat studies at high doses. After completion of the anabolic course, patients must be transitioned to an antiresorptive agent (bisphosphonate or denosumab) to maintain the gains in bone density.

Glucocorticoid-Induced Osteoporosis deserves separate attention. Any patient expected to take prednisone at a dose of 2.5 mg/day or more for 3 months or longer should receive calcium and vitamin D supplementation from the start, with bisphosphonate therapy initiated if the FRAX score warrants it or if the prednisone dose is 7.5 mg/day or higher. In glucocorticoid-induced osteoporosis, teriparatide may be more effective than bisphosphonates because the primary defect is suppressed bone formation rather than increased resorption.

05Differential Diagnosis and Distractors

06Traps and High-Yield Pearls

The most common way students lose points on osteoporosis questions is by confusing osteoporosis with osteomalacia. Both cause low bone density, both can present with fractures, and both respond to vitamin D. The discriminator is the lab profile: in osteoporosis, serum calcium, phosphorus, and alkaline phosphatase are all normal. The moment you see low calcium, low phosphorus, or elevated alkaline phosphatase, you should shift your thinking toward osteomalacia (or another metabolic bone disease) rather than primary osteoporosis.

A second common trap involves the T-score versus Z-score distinction. Test-writers will present a 35-year-old premenopausal woman or a young man with fractures and a DXA result. Students who reflexively apply the T-score criteria ($\le -2.5\backslash leq\; -2.5$) to diagnose osteoporosis in this population will choose the wrong answer. In premenopausal women, men under 50, and children, the Z-score is the appropriate metric, and a low Z-score should prompt a thorough search for secondary causes rather than immediate bisphosphonate therapy.

Another frequently tested concept is the abrupt discontinuation of denosumab. A vignette may describe a patient who was doing well on denosumab, stopped the medication (perhaps due to cost or insurance issues), and now presents months later with multiple new vertebral fractures. The tested concept is the rebound vertebral fracture syndrome that occurs when denosumab is not properly transitioned to a bisphosphonate.

Students also need to recognize the contraindication of bisphosphonates in patients with esophageal disorders (stricture, achalasia, Barrett esophagus, inability to sit upright) and in severe renal impairment (creatinine clearance below 30 to 35 mL/min). When these contraindications are present in a vignette, the correct answer shifts to denosumab (for renal impairment) or IV zoledronic acid (for esophageal issues, though renal function must still be adequate).

Finally, do not overlook glucocorticoid-induced osteoporosis as a "next best step" question. When a patient is started on chronic glucocorticoids, the tested action is initiating prophylactic calcium, vitamin D, and possibly a bisphosphonate at the time of glucocorticoid initiation, not waiting until a fracture occurs or a DXA shows low bone density. The core competency being tested across all osteoporosis questions is pattern recognition of the silent disease that declares itself through fragility fractures, combined with the ability to correctly sequence screening, diagnosis, and treatment based on patient-specific risk factors and contraindications.